美股生物医药板块消息早报（01-08-13）# Biology - 生物学
j*n
1 楼
今天前50大生物公司消息
1、Celgene Corporation (NASDAQ: CELG) provided its financial outlook for
2013 at the JPMorgan 31st Annual Healthcare Conference. In 2013, total net
product sales are expected to be approximately $6.0 billion, an 11.4% year-
over-year increase. Current: 89.42 +3.69 (4.30%)
简述：Celgene 2013年因为REVLIMID（治疗多发性骨髓瘤）的销售，盈利预增11.4%
2、Regeneron Pharmaceuticals Inc. (REGN), the drugmaker today celebrating
the 25th anniversary of its incorporation, fell the most in seven months
after reporting sales for its eye drug Eylea that disappointed investors.
Current:173.03 -9.50 (-5.20%)
简述：Regeneron耳疾药Eylea销售不及预期。
1、Celgene Corporation (NASDAQ: CELG) provided its financial outlook for
2013 at the JPMorgan 31st Annual Healthcare Conference. In 2013, total net
product sales are expected to be approximately $6.0 billion, an 11.4% year-
over-year increase. Current: 89.42 +3.69 (4.30%)
简述：Celgene 2013年因为REVLIMID（治疗多发性骨髓瘤）的销售，盈利预增11.4%
2、Regeneron Pharmaceuticals Inc. (REGN), the drugmaker today celebrating
the 25th anniversary of its incorporation, fell the most in seven months
after reporting sales for its eye drug Eylea that disappointed investors.
Current:173.03 -9.50 (-5.20%)
简述：Regeneron耳疾药Eylea销售不及预期。